Back

SK Life Science holds 2026 meeting to accelerate cenobamate growth

Verifying
  • SK Life Science held its 2026 Plan of Action meeting in Chicago.
  • More than 160 sales staff discussed second-half market-capture plans.
  • Cenobamate expansion includes an oral suspension and additional patient groups.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.